Ask AI

Complementing PARP Inhibition in Metastatic CRPC: Expert Insights and Strategies for Combining Therapeutic Approaches

Gain in-depth knowledge on the medical need and rationale for using PARP inhibitor–based treatment in patients with metastatic castration-resistant prostate cancer, including best practices in testing to inform treatment selection, recent guideline updates, and toxicity management, through an on-demand webcast with accompanying slides and an expert-written ClinicalThought.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Johnson & Johnson and Pfizer Inc.

Johnson & Johnson

Pfizer, Inc.